Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

Conclusions
The use of potent oral antiviral therapy can effectively suppress HBV replication in patients with CHB. However, the risk of HCC development in patients treated with oral antiviral agent is still significantly higher than patients with inactive stage CHB.

Source: Gut - October 31, 2014 Category: Gastroenterology Authors: Cho, J.-Y., Paik, Y.-H., Sohn, W., Cho, H. C., Gwak, G.-Y., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C. Tags: Cirrhosis, Hepatitis B, Hepatic cancer Hepatology Source Type: research